预激方案治疗老年人急性髓性白血病的临床研究  

Clinical research on priming regimen CAG in treatment of acute myeloid leukemia in elderly

作　　者：李尊昌[1] 付洪杰[2] 孙明东[1] 尹洪花[1] 杨胜[1] 

机构地区：[1]滨州市人民医院血液科,山东省滨州256610 [2]滨州医学院附属医院儿科

出　　处：《中国基层医药》2011年第17期2331-2332,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨预激方案（CAG方案）对老年急性髓系白血病的疗效和不良反应。方法应用CAG方案（CAG）组治疗老年急性髓系白血病患者32例，标准化疗方案（DA方案，DA组）治疗25例，比较两种方案的疗效和不良反应。结果CAG组与DA组完全缓解率、有效率差异均无统计学意义（均P〉0．05）；与DA组相比，CAG组骨髓恢复时间缩短、化疗相关死亡率低（t=3．03，x^2=4．05，P〈0．05）。结论对于老年急性髓系白血病，CAG方案疗效肯定、安全.Objective To explore the effect and adverse reaction of priming regimen CAG in treatment of acute myeloid leukemia in elderly. Methods 32 elderly patients with acute myelogenous leukemia were treated with CAG regimen and 25 cases with standard chemotherapy regimen（ DA regimen）. The effect and adverse reaction were compared between the two groups. Results There was no significant difference of the complete remission rate and effective rate between the two groups. The recovery time of bone marrow and death rate of CAG the regimen group were superior to those of the DA group. Conclusion CAG regimen was effctive and safe for elderly patients with acute myeloid leukemia.

关 键 词：抗肿瘤联合化疗方案 白血病 髓样 老年人 

分 类 号：R733[医药卫生—肿瘤]